These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

392 related articles for article (PubMed ID: 33259835)

  • 21. Bariatric surgery improves nonalcoholic fatty liver disease: a contemporary systematic review and meta-analysis.
    Fakhry TK; Mhaskar R; Schwitalla T; Muradova E; Gonzalvo JP; Murr MM
    Surg Obes Relat Dis; 2019 Mar; 15(3):502-511. PubMed ID: 30683512
    [TBL] [Abstract][Full Text] [Related]  

  • 22. FibroScan-aspartate aminotransferase score in an Asian cohort of non-alcoholic fatty liver disease and its utility in predicting histological resolution with bariatric surgery.
    Anand A; Elhence A; Vaishnav M; Singh AA; Rajput MS; Banyal V; Jindal V; Pathak P; Kumar P; Nayak B; Yadav R; Das P; Garg H; Agarwal L; Aggarwal S; Kumar R; Shalimar
    J Gastroenterol Hepatol; 2021 May; 36(5):1309-1316. PubMed ID: 33232525
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dulaglutide decreases plasma aminotransferases in people with Type 2 diabetes in a pattern consistent with liver fat reduction: a post hoc analysis of the AWARD programme.
    Cusi K; Sattar N; García-Pérez LE; Pavo I; Yu M; Robertson KE; Karanikas CA; Haupt A
    Diabet Med; 2018 Oct; 35(10):1434-1439. PubMed ID: 29869810
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluations of Lifestyle, Dietary, and Pharmacologic Treatments for Pediatric Nonalcoholic Fatty Liver Disease: A Systematic Review.
    Mann JP; Tang GY; Nobili V; Armstrong MJ
    Clin Gastroenterol Hepatol; 2019 Jul; 17(8):1457-1476.e7. PubMed ID: 29857146
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The association between serum fructosamine and random spot urine fructose levels with the severity of non-alcoholic fatty liver disease - an analytical cross-sectional study.
    Kamuzinzi H; Kgomo M; Rheeder P; Dada N; Bester P
    S Afr Med J; 2024 May; 114(6):e1748. PubMed ID: 39041504
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bariatric Surgery as an Efficient Treatment for Non-Alcoholic Fatty Liver Disease in a Prospective Study with 1-Year Follow-up : BariScan Study.
    Nickel F; Tapking C; Benner L; Sollors J; Billeter AT; Kenngott HG; Bokhary L; Schmid M; von Frankenberg M; Fischer L; Mueller S; Müller-Stich BP
    Obes Surg; 2018 May; 28(5):1342-1350. PubMed ID: 29119336
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Metabolic risk factors and incident advanced liver disease in non-alcoholic fatty liver disease (NAFLD): A systematic review and meta-analysis of population-based observational studies.
    Jarvis H; Craig D; Barker R; Spiers G; Stow D; Anstee QM; Hanratty B
    PLoS Med; 2020 Apr; 17(4):e1003100. PubMed ID: 32353039
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Incretin-based therapies for the treatment of non-alcoholic fatty liver disease: A systematic review and meta-analysis.
    Carbone LJ; Angus PW; Yeomans ND
    J Gastroenterol Hepatol; 2016 Jan; 31(1):23-31. PubMed ID: 26111358
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The effects of melatonin therapy on the treatment of patients with Non-alcoholic steatohepatitis: A systematic review and Meta-analysis on clinical trial studies.
    Akhavan Rezayat A; Ghasemi Nour M; Bondarsahebi Y; Hozhabrossadati SA; Amirkhanlou F; Akhavan Rezayat S; Kiani M; Imani B
    Eur J Pharmacol; 2021 Aug; 905():174154. PubMed ID: 34058202
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of pentoxifylline on nonalcoholic fatty liver disease: a meta-analysis.
    Du J; Ma YY; Yu CH; Li YM
    World J Gastroenterol; 2014 Jan; 20(2):569-77. PubMed ID: 24574727
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Association between telomere length and hepatic fibrosis in non-alcoholic fatty liver disease.
    Shin HK; Park JH; Yu JH; Jin YJ; Suh YJ; Lee JW; Kim W;
    Sci Rep; 2021 Sep; 11(1):18004. PubMed ID: 34504179
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of bariatric surgery on non-alcoholic fatty liver disease.
    Major P; Pędziwiatr M; Rubinkiewicz M; Stanek M; Głuszewska A; Pisarska M; Małczak P; Budzyński A; Budzyński P
    Pol Przegl Chir; 2017 Apr; 89(2):1-4. PubMed ID: 28537562
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety of semaglutide in non-alcoholic fatty liver disease.
    Zhu K; Kakkar R; Chahal D; Yoshida EM; Hussaini T
    World J Gastroenterol; 2023 Oct; 29(37):5327-5338. PubMed ID: 37899788
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nonalcoholic fatty liver disease is associated with an almost twofold increased risk of incident type 2 diabetes and metabolic syndrome. Evidence from a systematic review and meta-analysis.
    Ballestri S; Zona S; Targher G; Romagnoli D; Baldelli E; Nascimbeni F; Roverato A; Guaraldi G; Lonardo A
    J Gastroenterol Hepatol; 2016 May; 31(5):936-44. PubMed ID: 26667191
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Complete Resolution of Nonalcoholic Fatty Liver Disease After Bariatric Surgery: A Systematic Review and Meta-analysis.
    Lee Y; Doumouras AG; Yu J; Brar K; Banfield L; Gmora S; Anvari M; Hong D
    Clin Gastroenterol Hepatol; 2019 May; 17(6):1040-1060.e11. PubMed ID: 30326299
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Weight Loss After Bariatric Surgery Predicts an Improvement in the Non-alcoholic Fatty Liver Disease (NAFLD) Fibrosis Score.
    Yeo SC; Ong WM; Cheng KSA; Tan CH
    Obes Surg; 2019 Apr; 29(4):1295-1300. PubMed ID: 30635812
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Improvements in clinical characteristics of patients with non-alcoholic fatty liver disease, after an intervention based on the Mediterranean lifestyle: a randomised controlled clinical trial.
    Katsagoni CN; Papatheodoridis GV; Ioannidou P; Deutsch M; Alexopoulou A; Papadopoulos N; Papageorgiou MV; Fragopoulou E; Kontogianni MD
    Br J Nutr; 2018 Jul; 120(2):164-175. PubMed ID: 29947322
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combination of Aspartate Aminotranferase and Tumor Necrosis Factor-α as Non Invasive Diagnostic Tools for Non Alcoholic Steatohepatitis (NASH).
    Purnomo HD; Mundhofir FE; Kasno ; Sudijanto E; Darmono ; Daldiyono ; Djokomoeljanto R; Faradz SM
    Acta Med Indones; 2015 Jan; 47(1):16-23. PubMed ID: 25948763
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lipoprotein A, combined with alanine aminotransferase and aspartate aminotransferase, contributes to predicting the occurrence of NASH: a cross-sectional study.
    Zhang Y; He H; Zeng YP; Yang LD; Jia D; An ZM; Jia WG
    Lipids Health Dis; 2020 Jun; 19(1):134. PubMed ID: 32527258
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.